Published in J Immunol on March 01, 2004
High prevalence of low affinity peptide-MHC II tetramer-negative effectors during polyclonal CD4+ T cell responses. J Exp Med (2011) 1.76
Class II major histocompatibility complex tetramer staining: progress, problems, and prospects. Immunology (2008) 1.47
Manipulating antigenic ligand strength to selectively target myelin-reactive CD4+ T cells in EAE. J Neuroimmune Pharmacol (2009) 0.89
Uveitis-associated epitopes of retinal antigens are pathogenic in the humanized mouse model of uveitis and identify autoaggressive T cells. J Immunol (2011) 0.88
Enhancing the ability of experimental autoimmune encephalomyelitis to serve as a more rigorous model of multiple sclerosis through refinement of the experimental design. Comp Med (2009) 0.87
Targeting T lymphocytes for immune monitoring and intervention in autoimmune diabetes. Am J Ther (2005) 0.86
Dendritic cells and anergic type I NKT cells play a crucial role in sulfatide-mediated immune regulation in experimental autoimmune encephalomyelitis. J Immunol (2014) 0.83
Activated T cell subsets in human type 1 diabetes: evidence for expansion of the DR+ CD30+ subpopulation in new-onset disease. Clin Exp Immunol (2007) 0.82
Suppression of experimental autoimmune encephalomyelitis by interleukin-10 transduced neural stem/progenitor cells. J Neuroinflammation (2013) 0.81
Dynamic cross-regulation of antigen-specific effector and regulatory T cell subpopulations and microglia in brain autoimmunity. BMC Syst Biol (2013) 0.80
Autoimmune responses to brain following stroke. Transl Stroke Res (2012) 0.78
Major Histocompatibility Complex Class II Dextramers: New Tools for the Detection of antigen-Specific, CD4 T Cells in Basic and Clinical Research. Scand J Immunol (2015) 0.75
In Situ Peptide-MHC-II Tetramer Staining of Antigen-Specific CD4+ T Cells in Tissues. PLoS One (2015) 0.75
Antigen-specific immunotherapies in rheumatic diseases. Nat Rev Rheumatol (2017) 0.75
Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med (2003) 11.08
Interferon-regulatory factor 4 is essential for the developmental program of T helper 9 cells. Immunity (2010) 3.64
Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. J Neuroinflammation (2012) 3.12
Design and use of conditional MHC class I ligands. Nat Med (2006) 3.01
Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat Med (2010) 2.92
Cyclic adenosine monophosphate is a key component of regulatory T cell-mediated suppression. J Exp Med (2007) 2.88
Heterogeneous differentiation patterns of individual CD8+ T cells. Science (2013) 2.54
Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. Nat Nanotechnol (2013) 2.54
Generation of peptide-MHC class I complexes through UV-mediated ligand exchange. Nat Protoc (2006) 2.47
An essential role for tripeptidyl peptidase in the generation of an MHC class I epitope. Nat Immunol (2003) 2.38
Autocatalytic cleavage of Clostridium difficile toxin B. Nature (2007) 2.11
Nanoparticle size is a critical physicochemical determinant of the human blood plasma corona: a comprehensive quantitative proteomic analysis. ACS Nano (2011) 1.90
Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance. Nat Immunol (2009) 1.83
Antigen bias in T cell cross-priming. Science (2004) 1.82
Prediction of proteasome cleavage motifs by neural networks. Protein Eng (2002) 1.81
TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients. Oncoimmunology (2012) 1.78
The cancer antigenome. EMBO J (2012) 1.78
Conditional MHC class I ligands and peptide exchange technology for the human MHC gene products HLA-A1, -A3, -A11, and -B7. Proc Natl Acad Sci U S A (2008) 1.77
Recruitment of antigen-specific CD8+ T cells in response to infection is markedly efficient. Science (2009) 1.70
Gene-targeting of Phd2 improves tumor response to chemotherapy and prevents side-toxicity. Cancer Cell (2012) 1.69
Characterizing the N-terminal processing motif of MHC class I ligands. J Immunol (2008) 1.68
Triggering receptor expressed on myeloid cells-1 in neutrophil inflammatory responses: differential regulation of activation and survival. J Immunol (2004) 1.63
Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses in vivo. Blood (2006) 1.62
A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression. Nat Med (2005) 1.61
Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant. J Immunol (2006) 1.59
Antibodies against glycosylated native MOG are elevated in patients with multiple sclerosis. Neurology (2004) 1.58
Oligodendrocytes secrete exosomes containing major myelin and stress-protective proteins: Trophic support for axons? Proteomics Clin Appl (2007) 1.58
STAT5 regulates the self-renewal capacity and differentiation of human memory B cells and controls Bcl-6 expression. Nat Immunol (2005) 1.57
Balloon angioplasty compared with stenting for treatment of femoropopliteal occlusive disease: a meta-analysis. J Vasc Surg (2007) 1.56
Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol (2009) 1.56
One naive T cell, multiple fates in CD8+ T cell differentiation. J Exp Med (2010) 1.55
NFATc2 and NFATc3 transcription factors play a crucial role in suppression of CD4+ T lymphocytes by CD4+ CD25+ regulatory T cells. J Exp Med (2005) 1.55
In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens. Nat Med (2002) 1.54
Dissecting T cell lineage relationships by cellular barcoding. J Exp Med (2008) 1.53
Diffusion abnormality in Balo's concentric sclerosis: clues for the pathogenesis. Eur Neurol (2005) 1.50
Adoptive transfer of T-cell immunity. Trends Immunol (2002) 1.50
Hybrid PET/MRI of intracranial masses: initial experiences and comparison to PET/CT. J Nucl Med (2010) 1.48
Tumor rejection induced by CD70-mediated quantitative and qualitative effects on effector CD8+ T cell formation. J Exp Med (2004) 1.46
Differential kinetics of antigen-specific CD4+ and CD8+ T cell responses in the regression of retrovirus-induced sarcomas. J Immunol (2002) 1.46
Mechanisms and time course of neuronal degeneration in experimental autoimmune encephalomyelitis. Brain Pathol (2004) 1.45
Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Cancer Immunol Immunother (2014) 1.42
A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape. J Immunol (2002) 1.41
High-throughput identification of antigen-specific TCRs by TCR gene capture. Nat Med (2013) 1.40
Single-cell perforin and granzyme expression reveals the anatomical localization of effector CD8+ T cells in influenza virus-infected mice. Proc Natl Acad Sci U S A (2003) 1.39
Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis. J Neurol (2011) 1.39
Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiol Dis (2008) 1.39
Human CD4+CD25+ regulatory T cells: proteome analysis identifies galectin-10 as a novel marker essential for their anergy and suppressive function. Blood (2007) 1.38
Increased expression of DC-SIGN+IL-12+IL-18+ and CD83+IL-12-IL-18- dendritic cell populations in the colonic mucosa of patients with Crohn's disease. Eur J Immunol (2003) 1.33
Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function. J Immunol (2010) 1.33
C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia. Cancer Res (2004) 1.32
MAPPP: MHC class I antigenic peptide processing prediction. Appl Bioinformatics (2003) 1.31
TREM-1 ligand expression on platelets enhances neutrophil activation. Blood (2007) 1.31
Specific and redundant roles for NFAT transcription factors in the expression of mast cell-derived cytokines. J Immunol (2006) 1.29
FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis. Brain Res Bull (2007) 1.26
Interaction of TLR2 and TLR4 ligands with the N-terminal domain of Gp96 amplifies innate and adaptive immune responses. J Biol Chem (2006) 1.26
Selecting highly affine and well-expressed TCRs for gene therapy of melanoma. Blood (2007) 1.25
T-cell receptor gene therapy of established tumors in a murine melanoma model. J Immunother (2008) 1.24
MHC multimer technology: current status and future prospects. Curr Opin Immunol (2005) 1.24
Mast cells are crucial for early inflammation, migration of Langerhans cells, and CTL responses following topical application of TLR7 ligand in mice. Blood (2007) 1.23
Steady-state neutrophil homeostasis is dependent on TLR4/TRIF signaling. Blood (2012) 1.23
Therapeutic efficacy of intranasally delivered mesenchymal stem cells in a rat model of Parkinson disease. Rejuvenation Res (2011) 1.21
The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes. Autoimmun Rev (2013) 1.21
Frequency and syndrome specificity of antibodies to aquaporin-4 in neurological patients with rheumatic disorders. Mult Scler (2011) 1.19
Intravital imaging of fluorescent markers and FRET probes by DNA tattooing. BMC Biotechnol (2007) 1.19
HLA-G expression defines a novel regulatory T-cell subset present in human peripheral blood and sites of inflammation. Blood (2007) 1.19
Risk for myasthenia gravis maps to a (151) Pro→Ala change in TNIP1 and to human leukocyte antigen-B*08. Ann Neurol (2012) 1.19
Cutting edge: priming of CTL by transcutaneous peptide immunization with imiquimod. J Immunol (2005) 1.16
EAE: imperfect but useful models of multiple sclerosis. Trends Mol Med (2011) 1.16
Intrathymic and extrathymic development of human plasmacytoid dendritic cell precursors in vivo. Blood (2002) 1.16
Generation of T cell help through a MHC class I-restricted TCR. J Immunol (2006) 1.15
FoxP3+ regulatory T cells essentially contribute to peripheral CD8+ T-cell tolerance induced by steady-state dendritic cells. Proc Natl Acad Sci U S A (2009) 1.15
Technical performance evaluation of a human brain PET/MRI system. Eur Radiol (2012) 1.14
Preclinical development of T cell receptor gene therapy. Curr Opin Immunol (2009) 1.14
Inhibition of cAMP degradation improves regulatory T cell-mediated suppression. J Immunol (2009) 1.13
IL-22 is produced by innate lymphoid cells and limits inflammation in allergic airway disease. PLoS One (2011) 1.13
A proteomic approach to tumour target identification using phage display, affinity purification and mass spectrometry. Eur J Cancer (2005) 1.11
Balancing between antitumor efficacy and autoimmune pathology in T-cell-mediated targeting of carcinoembryonic antigen. Cancer Res (2008) 1.11
Methylprednisolone increases neuronal apoptosis during autoimmune CNS inflammation by inhibition of an endogenous neuroprotective pathway. J Neurosci (2003) 1.11
Prospects and limitations of T cell receptor gene therapy. Curr Gene Ther (2011) 1.11
Functional human antigen-specific T cells produced in vitro using retroviral T cell receptor transfer into hematopoietic progenitors. J Immunol (2007) 1.10
Host glycoprotein Gp96 and scavenger receptor SREC interact with PorB of disseminating Neisseria gonorrhoeae in an epithelial invasion pathway. Cell Host Microbe (2007) 1.10
TCR gene therapy of spontaneous prostate carcinoma requires in vivo T cell activation. J Immunol (2008) 1.08
Features of TAP-independent MHC class I ligands revealed by quantitative mass spectrometry. Eur J Immunol (2008) 1.08
Increased antigen presentation efficiency by coupling antigens to MHC class I trafficking signals. J Immunol (2008) 1.08
Early growth response transcription factors are required for development of CD4(-)CD8(-) thymocytes to the CD4(+)CD8(+) stage. J Immunol (2002) 1.07
The immune system strikes back: cellular immune responses against indoleamine 2,3-dioxygenase. PLoS One (2009) 1.07
Targeting self-antigens through allogeneic TCR gene transfer. Blood (2006) 1.06
Expression of the proteasome activator PA28 rescues the presentation of a cytotoxic T lymphocyte epitope on melanoma cells. Cancer Res (2002) 1.06
Identification of HLA-DR-bound peptides presented by human bronchoalveolar lavage cells in sarcoidosis. J Clin Invest (2007) 1.05
Peptide-induced negative selection of thymocytes activates transcription of an NF-kappa B inhibitor. Mol Cell (2002) 1.04
Cathepsin V is involved in the degradation of invariant chain in human thymus and is overexpressed in myasthenia gravis. J Clin Invest (2003) 1.04
Ipilimumab-induced sarcoidosis in a patient with metastatic melanoma undergoing complete remission. J Clin Oncol (2011) 1.04
Quantitative analysis of prion-protein degradation by constitutive and immuno-20S proteasomes indicates differences correlated with disease susceptibility. J Immunol (2004) 1.04
High-throughput identification of potential minor histocompatibility antigens by MHC tetramer-based screening: feasibility and limitations. PLoS One (2011) 1.03
Notch1 and its ligand Jagged1 are present in remyelination in a T-cell- and antibody-mediated model of inflammatory demyelination. Acta Neuropathol (2006) 1.03
Polo-box domain inhibitor poloxin activates the spindle assembly checkpoint and inhibits tumor growth in vivo. Am J Pathol (2011) 1.03